KRAS and NRAS testing is now a mandatory procedure for all CRC patients considered for cetuximab and panitumumab treatment, as these drugs have virtually null efficacy in patients with mutation but provide reasonable benefit in the wild-type cases. This evidence concerns the gene NRAS and colorectal carcinoma.